The effectiveness of psychological support with the use of hepato-immunoprotectors as predictors in drug therapy of tuberculosis

The aim of the study was to evaluate the effectiveness of psychological (adherence to treatment) and accompanying drug therapy depending on the form of pulmonary tuberculosis. The results of complex therapy of 326 patients with various forms of pulmonary tuberculosis are considered. All patients received etiotropic treatment, taking into account the sensitivity of the pathogen to anti-tuberculosis drugs, as well as support therapy, including psychological support and, if indicated, hepatoprotective therapy with Remaxol. When analyzing the dependence of the psychoemotional state of patients on the form of the tuberculous process in the lungs, it was noted that high adherence to therapy was observed in one third of patients in all groups (DTL — 26.1%, ITL — 28.6%, FCTL — 32.8% and ATL — 31.8%, respectively, P>0.05). The results obtained may be associated with a high level of resistance of mycobacterium tuberculosis excreted from pa tients: out of 232 patients with low adherence to treatment (NUP and UUP), 97 (36.2%) showed drug resistance of the pathogen to two or more etiotropic drugs, which, in turn, caused prescription of reserve drugs. Thus, the determination of the level of adherence to treatment is justified and is aimed at correcting the psychological support of patients with pulmonary tuberculosis, which makes it possible to increase the effectiveness of therapy in these patients. The appointment of the latter in a number of patients led to the development of hepatotoxic reactions, which served as the basis for the inclusion in the therapy regimens of the accompaniment of Remaxol (intravenous drip of 400 ml, course No. 5–7). Pronounced hepatoprotective (improved transaminase parameters) and insignificant immunoprotective (positive dynamics of the cytokine profile) effects were noted during treatment. The noted changes in the immunogram can be associated with the proven antioxidant and membrane stabilizing effect of succinic acid, which is part of Remaxol. These changes require further research.

1. Ravil'one M., Korobitsin A. A. Likvidatsiya tuberkuleza — novaya strategiya VOZ v eru ustojchivogo razvitiya, vklad Rossijskoj Federatsii. Tuberkulez i Bolezni Legkikh. 2016; 84 (11): 8–15. doi 10.21292/2075-1230-2016-94-11-7-15. (in Russian)

2. Testov V. V., Sterlikov S. A., Vasil'eva I. A., Sidorova I. A., Mikhajlova Jyu. V. Federal'nyj registr lits, bol'nykh tuberkulezom, kak instrument monitoringa vliyaniya protivoepidemicheskikh meropriyatij, vyzvannykh pandemiej COVID-19, na sistemu okazaniya protivotuberkuleznoj pomoshchi. Tuberkulez i Bolezni Legkikh. 2020; (98) 11: 6–11. doi:10.21292/2075-1230-2020-98-11-6-11.

3. Belostotskij A.V., Kasaeva T.Ch., Kuz-'mina N.V., Nelidova N.V. Problema priverzhennosti bol'nykh tuberkulezom k lechenijyu. Tuberkulez i Bolezni Legkikh. 2015; (4): 4–9. (in Russian)

4. Kolomiets V.M., Medvedeva N.N. Kliniko-psikhologicheskie osobennosti u bol'nykh razlichnymi formami tuberkuleza legkikh. Tuberkulez i Sotsial'no Znachimye Zabolevaniya. 2019;1: 79–80. (in Russian)

5. Sherstenev G.V., Skornyakov S. N., Podaeva V. A., Sherstenev S.V., Tsvetkov A. I. Mul'tidistsiplinarnyj podkhod v rabote po formirovanijyu priverzhennosti lechenijyu bol'nykh tuberkulezom. Tuberkulez i Bolezni Legkikh. 2017; 95 (1): 34–41 doi 10.21292/2075-1230-2017-95-1-34-41. (in Russian)

6. Starshinova A. A., Belyaeva E. N., Panteleev A. M., Pavlova M. V. Primenenie gepatoprotektorov na fone khimioterapii tuberkuleza: obzor otechestvennykh i zarubezhnykh issledovanij. Tuberkulez i bolezni legkikh 2018; 96(10): 63–69. doi 10.21292/2075-1230-2018-96-10-63-69. (in Russian)

7. Jyudin S.A., Barkanova O.N, Borzenko A.S., Delarjyu V.V. Reabilitatsiya vo ftiziatrii: komplementarnost' meditsinskikh, sotsial-'nykh i psikhologicheskikh faktorov: Monografiya. Volgograd: Izd-vo VolgGMU, 2017. 301. (in Russian)

8. Sterlikov S.A., Galkin V.B., Rusakova L.I., Ponomarev S.B., Gordina A.V. Rezul'taty lecheniya bol'nykh tuberkulezom v 2018 godu. Sovremennye Problemy Zdravookhraneniya i Meditsinskoj Statistiki 2019; 3: 28–68. doi 10.24411/2312-2935-2019-10054. (in Russian)

9. Yasinov D.A., Polovinko I.A., Smagina L.T. Effektivnost' psikhologicheskogo soprovozhdeniya priverzhennosti k lechenijyu tuberkuleza na statsionarnom etape. Tuberkulez, Sotsial'nye Bolezni, VICh. 2014; 16 (1): 55–59. (in Russian)

10. Stel'makh V.V., Kozlov V.K., Ivanova V.F., Samusenko I.A. Effektivnost' infuzionnogo gepatotropnogo preparata remaksol v patogeneticheskoj terapii khronicheskikh virusnykh gepatitov na tsirroticheskoj stadii. Terapevticheskij Arkhiv. 2015; 87(8): 67–72. doi: 10.17116/terarkh201587867-72. (in Russian)

11. Sukhanov D.S. Effektivnost' gepatoprotektornogo dejstviya i otsenka riska pri ispol'zovanii reamberina, remaksola i ademetionina u bol'nykh tuberkulezom organov dykhaniya s lekarstvennymi porazheniyami pecheni. Terapevticheskij Arkhiv. 2012; 84 (11): 26–29. (in Russian)

12. Patent na izobretenie Rossii RU № 2611398 «Sposob povysheniya effektivnosti lecheniya bol'nykh tuberkulezom» 21.02.2017. Registratsiya v Gosudarstvennom registre izobretenij RF 21 fevralya 2017 g. (in Russian)